Efficacy of a Therapeutic Combination of Dronabinol and PEA for Tourette Syndrome

Inclusion Criteria: * Adult between 18-60 years of age * Meet DSM-5 criteria for the diagnosis of Tourette syndrome * Significant current tic symptoms: YGTSS total tic score greater than or equal to 22 at baseline * On stable psychiatric medication regimen for a minimum of 4 weeks prior to beginning the trial * Accepted method of birth control Exclusion Criteria: * Comorbid bipolar disorder, psychotic disorder, substance use disorder, developmental disorder or intellectual disability (IQ\<70) * Recent change (less than 4 weeks) in other medications that have potential effects on tic severity (such as alpha-2 agonists (guanfacine, clonidine or prazosin), SSRIs, clomipramine, naltrexone, lithium, anxiolytics, topiramate, baclofen etc.). Medication change is defined to include dose changes or medication discontinuation. * Recent change in behavioral treatment for Tourette syndrome or comorbid conditions (i.e. OCD) within the last 4 weeks or initiation of behavioral therapy for tics within the last 12 weeks. * Taking any co-medications (over the counter or prescription), food supplements/additives which can have a drug interaction with dronabinol or PEA. * Positive pregnancy test or drug screening test * History of cannabis dependence * Significant Medical Comorbidity * History of hypersensitivity to any cannabinoid or sesame oil